BMIQ7
MCID: BDY012
MIFTS: 43

Body Mass Index Quantitative Trait Locus 7 (BMIQ7)

Categories: Bone diseases, Genetic diseases, Mental diseases, Metabolic diseases

Aliases & Classifications for Body Mass Index Quantitative Trait Locus 7

MalaCards integrated aliases for Body Mass Index Quantitative Trait Locus 7:

Name: Body Mass Index Quantitative Trait Locus 7 57 13
Obesity 57 70
Obesity, Susceptibility to, Bmiq7 57
Obesity, Susceptibility to 57
Obesity Bmiq7 57
Bmiq7 57

Classifications:



External Ids:

OMIM® 57 608410
UMLS 70 C0028754

Summaries for Body Mass Index Quantitative Trait Locus 7

MalaCards based summary : Body Mass Index Quantitative Trait Locus 7, also known as obesity, is related to body mass index quantitative trait locus 11 and body mass index quantitative trait locus 19, and has symptoms including symptoms, high weight and obesity, metabolically benign. An important gene associated with Body Mass Index Quantitative Trait Locus 7 is BMIQ7 (Obesity, Susceptibility To, On Chromosome 4). The drugs Dalteparin and Letrozole have been mentioned in the context of this disorder. Affiliated tissues include liver, heart and bone.

More information from OMIM: 608410

Related Diseases for Body Mass Index Quantitative Trait Locus 7

Diseases in the Body Mass Index Quantitative Trait Locus 11 family:

Body Mass Index Quantitative Trait Locus 9 Body Mass Index Quantitative Trait Locus 8
Body Mass Index Quantitative Trait Locus 1 Body Mass Index Quantitative Trait Locus 2
Body Mass Index Quantitative Trait Locus 3 Body Mass Index Quantitative Trait Locus 4
Body Mass Index Quantitative Trait Locus 10 Body Mass Index Quantitative Trait Locus 7
Body Mass Index Quantitative Trait Locus 5 Body Mass Index Quantitative Trait Locus 6
Body Mass Index Quantitative Trait Locus 12 Body Mass Index Quantitative Trait Locus 13
Body Mass Index Quantitative Trait Locus 14 Body Mass Index Quantitative Trait Locus 15
Body Mass Index Quantitative Trait Locus 18 Body Mass Index Quantitative Trait Locus 19
Body Mass Index Quantitative Trait Locus 20

Diseases related to Body Mass Index Quantitative Trait Locus 7 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1941)
# Related Disease Score Top Affiliating Genes
1 body mass index quantitative trait locus 11 12.0
2 body mass index quantitative trait locus 19 11.9
3 leptin deficiency or dysfunction 11.9
4 body mass index quantitative trait locus 4 11.8
5 body mass index quantitative trait locus 12 11.8
6 body mass index quantitative trait locus 9 11.8
7 body mass index quantitative trait locus 8 11.8
8 body mass index quantitative trait locus 18 11.8
9 body mass index quantitative trait locus 14 11.8
10 body mass index quantitative trait locus 10 11.8
11 leptin receptor deficiency 11.5
12 cohen syndrome 11.5
13 obesity-hypoventilation syndrome 11.5
14 obesity, early-onset, with adrenal insufficiency and red hair 11.5
15 wilson-turner x-linked mental retardation syndrome 11.5
16 abdominal obesity-metabolic syndrome 3 11.5
17 mehmo syndrome 11.5
18 morbid obesity and spermatogenic failure 11.5
19 abdominal obesity-metabolic syndrome quantitative trait locus 2 11.5
20 proprotein convertase 1/3 deficiency 11.4
21 abdominal obesity-metabolic syndrome 1 11.4
22 obesity, hyperphagia, and developmental delay 11.4
23 mental retardation, truncal obesity, retinal dystrophy, and micropenis syndrome 11.4
24 abdominal obesity-metabolic syndrome 4 11.4
25 hypothalamic obesity 11.4
26 spastic paraplegia, intellectual disability, nystagmus, and obesity 11.4
27 momo syndrome 11.4
28 retinal dystrophy and obesity 11.4
29 chung-jansen syndrome 11.4
30 chops syndrome 11.4
31 genetic obesity 11.3
32 wilms tumor, aniridia, genitourinary anomalies, mental retardation, and obesity syndrome 11.3
33 body mass index quantitative trait locus 20 11.3
34 fatty liver disease 11.3
35 non-alcoholic fatty liver disease 11.3
36 hydrocephalus obesity hypogonadism 11.3
37 ayazi syndrome 11.3
38 rohhad 11.2
39 coenzyme q10 deficiency, primary, 2 11.2
40 aniridia - ptosis - intellectual disability - familial obesity 11.2
41 type 2 diabetes mellitus 11.2
42 prader-willi syndrome 11.2
43 glucose intolerance 11.2
44 body mass index quantitative trait locus 1 11.2
45 polycystic ovary syndrome 11.2
46 eating disorder 11.2
47 alstrom syndrome 11.2
48 x-linked intellectual disability - short stature - obesity 11.2
49 man1b1-cdg 11.1
50 bardet-biedl syndrome 11.1

Graphical network of the top 20 diseases related to Body Mass Index Quantitative Trait Locus 7:



Diseases related to Body Mass Index Quantitative Trait Locus 7

Symptoms & Phenotypes for Body Mass Index Quantitative Trait Locus 7

Clinical features from OMIM®:

608410 (Updated 20-May-2021)

UMLS symptoms related to Body Mass Index Quantitative Trait Locus 7:


symptoms; high weight; obesity, metabolically benign; monogenic obesity

Drugs & Therapeutics for Body Mass Index Quantitative Trait Locus 7

Drugs for Body Mass Index Quantitative Trait Locus 7 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 957)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dalteparin Approved Phase 4 9005-49-6
2
Letrozole Approved, Investigational Phase 4 112809-51-5 3902
3
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
4
Ticagrelor Approved Phase 4 274693-27-5 9871419
5
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
6
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
7
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
8
Indapamide Approved Phase 4 26807-65-8 3702
9
Linagliptin Approved Phase 4 668270-12-0 10096344
10
Metyrapone Approved, Investigational Phase 4 54-36-4 4174
11
Linezolid Approved, Investigational Phase 4 165800-03-3 441401
12
Tolnaftate Approved, Investigational, Vet_approved Phase 4 2398-96-1 5510
13
Zonisamide Approved, Investigational Phase 4 68291-97-4 5734
14
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
15
Bismuth subsalicylate Approved, Vet_approved Phase 4 14882-18-9 53629521
16
Clarithromycin Approved Phase 4 81103-11-9 84029
17
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
18
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
19
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585 135398745
20
Fenofibrate Approved Phase 4 49562-28-9 3339
21
Atorvastatin Approved Phase 4 134523-00-5 60823
22
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
23
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
24
Ziprasidone Approved Phase 4 146939-27-7 60854
25
Calcium carbonate Approved, Investigational Phase 4 471-34-1
26
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
27
Meropenem Approved, Investigational Phase 4 96036-03-2, 119478-56-7 64778 441130
28
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
29
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
30
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
31
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
32
Magnesium oxide Approved Phase 4 1309-48-4 14792
33
Enoxaparin Approved Phase 4 9005-49-6 772
34
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
35
Repaglinide Approved, Investigational Phase 4 135062-02-1 65981
36
Losartan Approved Phase 4 114798-26-4 3961
37
Coal tar Approved Phase 4 8007-45-2
38
Ofloxacin Approved Phase 4 82419-36-1 4583
39
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
40
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
41
Tedizolid Approved, Investigational Phase 4 856866-72-3
42
Tedizolid phosphate Approved Phase 4 856867-55-5
43
Bazedoxifene Approved, Investigational Phase 4 198481-32-2
44
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
45
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
46
Doxorubicin Approved, Investigational Phase 4 23214-92-8 31703
47
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
48
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
49
Phenylephrine Approved Phase 4 59-42-7 6041
50
Risedronate Approved, Investigational Phase 4 105462-24-6 5245

Interventional clinical trials:

(show top 50) (show all 7845)
# Name Status NCT ID Phase Drugs
1 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis: a Randomized, Investigator-blinded Study Unknown status NCT01439425 Phase 4
2 The Effect of Obesity in Dexmedetomidine Metabolic Clearance Unknown status NCT02557867 Phase 4 Dexmedetomidine
3 Vitamin D Concentrations and Their Effect on Glucose Metabolism in Pediatrics Unknown status NCT01386736 Phase 4 Vitamin D drops;Placebo drops
4 Double-blind Randomized Trial Using Oral Metformin Versus Placebo in the Treatment of Acanthosis Nigricans in Children With Obesity Unknown status NCT02438020 Phase 4 Metformin
5 The Effect of Vitamin A Supplementation on CD4+ T-cell Secretion in Obese Individuals Unknown status NCT01405352 Phase 4
6 Levonorgestrel-releasing Intrauterine Device Effects on Hemostatic and Arterial Function of Obese Women Unknown status NCT01320917 Phase 4
7 Study of the Concentrations of Long Acting Morphine After Oral Absorption in Subjects Who Underwent Gastric Bypass (OBEMO 2) Unknown status NCT02641301 Phase 4 Sustained release morphine sulfate, 30 mg
8 International, Multi Centre, Open, Prospective, Randomized Study: Banded Versus Conventional Laparoscopic Roux-en-Y (GABY) Unknown status NCT01015469 Phase 4
9 Comparing the Efficacy of Two Frequently Used Doses of Enoxaparin for VTE Prophylaxis After Bariatric Surgery Unknown status NCT01970202 Phase 4 40mg Enoxaparin;60mg Enoxaparin
10 Evaluation of the Effects of Laying Early (Between 12 and 16) a Gastric Band on the Prevention of Morbid Obesity in Late Adolescence. Randomized Checked Against Standard Management of Obesity in This Population. Unknown status NCT01700738 Phase 4
11 Early Detection of Atherosclerosis in the Primary Care Setting: a Randomized Trial to Assess the Efficacy of a Novel Strategy in the Primary Prevention of Cardiovascular Diseases. Unknown status NCT00734123 Phase 4 Simvastatin or Atorvastatin;Enalapril;Aspirin or clopidogrel;Rimonabant
12 PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor Unknown status NCT02698618 Phase 4 Randomization
13 Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients Unknown status NCT02933788 Phase 4 Cilostazol;Acetylsalicylic acid
14 The Effect of Moxonidine and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension: a Randomised, Double Blind, Active Comparator Clinical Trial Unknown status NCT01360710 Phase 4 Moxonidine;Irbesartan
15 Prevention and Control of Obesity in Primary School Children in Tehran Unknown status NCT02082080 Phase 4
16 A Study of the Pharmacokinetics of Dexmedetomidine in Morbid Obesity. Unknown status NCT01864187 Phase 4 Dexmedetomidine
17 Comparing Dexlansoprazole With Double-dose Lansoprazole to Achieve Sustained Symptomatic Response in Overweight and Obesity Patients With Reflux Esophagitis in Los Angeles Grades A & B Unknown status NCT02759393 Phase 4 Dexlansoprazole;Lansoprazole
18 Assessment of the Effect of Moxonidine and Diet on Cardiac, Renal and Endothelial Function in Young Subjects With Abdominal Obesity Unknown status NCT01180231 Phase 4 Moxonidine (Physiotens)
19 The Therapeutic Effect of Catgut Embedding in Obesity-A Randomized, Double-blind, Placebo-controlled Clinical Trial Unknown status NCT02276235 Phase 4
20 The Effect of Probiotics on Obesity. Metabolic Endotoxemia and Inflammation Unknown status NCT03883685 Phase 4
21 Double Blinded Randomised Trial Comparing Metformin Versus Placebo in NASH Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
22 Effect of Saxagliptin on Body Fat , Glucose and Beta Cell Function in Patients With Newly Diagnosed Pre-Diabetes Mellitus and Obesity Unknown status NCT01960205 Phase 4 Saxagliptin;saxagliptin;metformin
23 Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Overweight and Obesity Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Randomized Control Study Unknown status NCT02999841 Phase 4 Acarbose;Vildagliptin
24 Healthy Opportunities for Physical Activity and Nutrition (HOP'N) After-School Project Unknown status NCT01015599 Phase 4
25 Endobarrier Treatment in Obese Subjects With T2DM Unknown status NCT01718457 Phase 4
26 Laparoscopic Non Banded Vertical (Magenstrasse and Mill) Gastroplasty In Bariatric Surgery. Morbidity and Results on Weight Loss and Associated Co-morbidities Unknown status NCT02050477 Phase 4
27 Laparoscopic Roux-en-Y Gastric Bypass vs. Laparoscopic BPD-Duodenal Switch for Superobesity (BMI > 50 kg/m2)- A Randomized Clinical Trial Unknown status NCT00327912 Phase 4
28 Prospective Randomized Study of Effects of Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy Unknown status NCT00667706 Phase 4
29 Prospective, Pharmacokinetic Study for Determination of the Relationship Between Lean Body Weight and Anti-Xa Activity 4 Hours After Subcutaneous Injection of 5700 IU Nadroparin in Morbidly Obese Patients After Bariatric Surgery. Unknown status NCT02295150 Phase 4 Nadroparin
30 Gut Hormones as Mediators of Different Weight Loss Responses After Roux-en-Y Gastric Bypass Unknown status NCT02374632 Phase 4
31 Correlation of Postoperative VAS Values and Body Mass Index in Patients Undergoing Abdominal Surgery: A Clinical Trial Unknown status NCT02017314 Phase 4 Morphine
32 Laparoscopic Bariatric Surgery: Impact of the Level of Neuromuscular Blockade on Surgical Conditions - Comparison Between Moderate and Deep Neuromuscular Blockade Unknown status NCT02118844 Phase 4 rocuronium
33 Double-blind and Placebo-controlled Study on Intervention Effect of n-3 Fatty Acids on Glucose and Lipid Homeostasis Disorders in Obese/Diabetic Populations Unknown status NCT03708887 Phase 4 Low dose omega-3 fatty acid supplementation;High dose omega-3 fatty acid supplementation;Control drug
34 Heparin Management for Cardiopulmonary Bypass in Cardiac Surgery: A Prospective, Comparative and Randomized Study Evaluating a Dosage Based on the Ideal Body Weight in Obese Patients Unknown status NCT02675647 Phase 4 Heparin, IV route, based on patients body weights (UI/kg);Protamin administration
35 HYpertension Therapy With Valsartan Versus EpleRenone for Obese Patients: A Randomized Clinical Trial Unknown status NCT03476616 Phase 4 Eplerenone (-based therapy) arm;Valsartan (-based therapy) arm
36 Ultrasonographic Modification of Liver Steatosis and Visceral Fat Induced by Treatment With Losartan and Simvastatin in Hypertensive Normocholesterolemic Obese Patients Unknown status NCT00669435 Phase 4 Losartan + Simvastatin;Amlodipine + Simvastatin
37 Oral Tramadol Versus Oral Celecoxib for Post-perineal Repair Analgesia After Spontaneous Vaginal Birth in Obese Women: A Randomised Controlled Trial Unknown status NCT03694873 Phase 4 Tramadol Hydrochloride;Celecoxib 200mg
38 The Effects of Cortisol Blockade on Nutritional Sympathetic Nervous System Responsiveness in Overweight and Obese Subjects With Metabolic Syndrome Unknown status NCT01620684 Phase 4 metyrapone;placebo
39 The Need of Dosing Adjustment for Simvastatin in Obese Patients Post Bariatric Surgery- Laparoscopic Sleeve Gastrectomy (LSG) Unknown status NCT03571802 Phase 4 Simvastatin
40 What is the Effects of Incretin on the Blood Pressure and Lipid in Overweight or Obese Diabetes Patients With Masked Hypertension: Liraglutide Plus Mitiglinide Comparing Metformin Plus Mitiglinide or Mitiglinide Alone(BLOOD STUDY) Unknown status NCT02503943 Phase 4 "Liraglutide" and "Mitiglinide";"Metformin" and "Mitiglinide";"Mitiglinide"
41 The Effect of TRADJENTA ® (LINAGLIPTIN) on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects Unknown status NCT02372630 Phase 4 Linagliptin;Placebo
42 Evaluation of Family Intervention Program for the Treatment of Overweight or Obese Children (Nereu Program): Randomized Clinical Trial Unknown status NCT01878994 Phase 4
43 Study of Metabolic Effects of EndoBarrier Versus Intragastric Balloon in Obese Patients With Type 2 Diabetes. Unknown status NCT01848795 Phase 4
44 Combined Effects of SGLT2 Inhibition and GLP-1 Receptor Agonism on Food Intake, Body Weight and Central Satiety and Reward Circuits in Obese T2DM Patients Unknown status NCT03361098 Phase 4 Dapagliflozin 10mg;Exenatide
45 Pharmacokinetic and Pharmacodynamic Evaluation of Linezolid Administered Intravenously in MRSA-positive, Morbidly Obese Patients With Pneumonia Unknown status NCT01805284 Phase 4 Linezolid
46 Influence of the Aromatase Inhibitor Letrozole on Heart and Liver Function in Obese Men Unknown status NCT02097680 Phase 4 Letrozole;Placebo
47 Retroclavicular Approach vs Infraclavicular Approach for Brachial Plexus Block in Obese Unknown status NCT02990702 Phase 4 Bupivacaine
48 Structured Exerise Training in Infertile Obese Patients Treated With Assisted Reproductive Techniques: a Randomized Controlled Trial Unknown status NCT01892111 Phase 4
49 Metformin Treatment for Preventing Gestational Diabetes in High-risk Patients Unknown status NCT00883259 Phase 4 Metformin
50 Sildenafil Activates Browning of White Adipose and Improves Insulin Sensitivity in Human Adults Unknown status NCT02524184 Phase 4 sildenafil;placebo

Search NIH Clinical Center for Body Mass Index Quantitative Trait Locus 7

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Benzphetamine
Benzphetamine hydrochloride
Dexfenfluramine
Dexfenfluramine Hydrochloride
Diethylpropion
Diethylpropion Hydrochloride
Fenfluramine
Fenfluramine Hydrochloride
lorcaserin
lorcaserin hydrochloride
Mazindol
Methamphetamine
orlistat
phendimetrazine
PHENDIMETRAZINE HYDROCHLORIDE
phendimetrazine tartrate
Phenmetrazine
Phenmetrazine Hydrochloride
Phentermine
Phentermine Hydrochloride
PHENTERMINE RESIN
Phenylpropanolamine
Phenylpropanolamine Hydrochloride
sibutramine
SIBUTRAMINE HYDROCHLORIDE

Genetic Tests for Body Mass Index Quantitative Trait Locus 7

Anatomical Context for Body Mass Index Quantitative Trait Locus 7

MalaCards organs/tissues related to Body Mass Index Quantitative Trait Locus 7:

40
Liver, Heart, Bone, Breast, Endothelial, Brain, Kidney

Publications for Body Mass Index Quantitative Trait Locus 7

Articles related to Body Mass Index Quantitative Trait Locus 7:

(show top 50) (show all 30003)
# Title Authors PMID Year
1
TBC1D1 is a candidate for a severe obesity gene and evidence for a gene/gene interaction in obesity predisposition. 61 57
16893906 2006
2
R125W coding variant in TBC1D1 confers risk for familial obesity and contributes to linkage on chromosome 4p14 in the French population. 57
18325908 2008
3
Evidence of a novel quantitative-trait locus for obesity on chromosome 4p in Mexican Americans. 57
14740316 2004
4
A major predisposition locus for severe obesity, at 4p15-p14. 57
11957135 2002
5
Childhood exposure to parental smoking and life-course overweight and central obesity. 61
33305629 2021
6
Attitudes, behaviours and strategies towards obesity patients in primary care: A qualitative interview study with general practitioners in Germany. 61
33749477 2021
7
Blood pro-oxidant/antioxidant balance in young men with class II obesity after 20 sessions of whole body cryostimulation: a preliminary study. 61
33560197 2021
8
The effect of body mass index on the development of acute kidney injury and mortality in intensive care unit: is obesity paradox valid? 61
33745415 2021
9
Drosophila as a useful model for understanding the evolutionary physiology of obesity resistance and metabolic thrift. 61
33704003 2021
10
Association between rs174537 FADS1 polymorphism and immune cell profiles in abdominal and femoral subcutaneous adipose tissue: an exploratory study in adults with obesity. 61
33595419 2021
11
Estimating the prevalence of overweight and obesity in Nigeria in 2020: a systematic review and meta-analysis. 61
33783281 2021
12
Brown and beige adipose tissue: a novel therapeutic strategy for obesity and type 2 diabetes mellitus. 61
33403891 2021
13
Swertiamarin supplementation prevents obesity-related chronic inflammation and insulin resistance in mice fed a high-fat diet. 61
33794740 2021
14
The role and research progress of the balance and interaction between regulatory T cells and other immune cells in obesity with insulin resistance. 61
33472506 2021
15
Development of novel functional snacks containing nano-encapsulated resveratrol with anti-diabetic, anti-obesity and antioxidant properties. 61
33691210 2021
16
Prenatal exposure to persistent organic pollutants and markers of obesity and cardiometabolic risk in Spanish adolescents. 61
33711537 2021
17
Ambient air pollution and obesity in school-aged children and adolescents: A multicenter study in China. 61
33524680 2021
18
Sensory cue reactivity: Sensitization in alcohol use disorder and obesity. 61
33587959 2021
19
No influence of obesity on mid-term clinical, functional, and radiological results after computer-navigated total knee arthroplasty using a gap balancing technique. 61
33717948 2021
20
Curcumin analogue C66 attenuates obesity-induced renal injury by inhibiting chronic inflammation. 61
33761621 2021
21
Dyspnea during exercise and voluntary hyperpnea in women with obesity. 61
33581294 2021
22
Association and potential mediators between socioeconomic status and childhood overweight/obesity. 61
33617865 2021
23
Obesity and aging: Molecular mechanisms and therapeutic approaches. 61
33556548 2021
24
Low-Molecular-Weight Heparin and Fondaparinux Use in Pediatric Patients With Obesity. 61
32864984 2021
25
Index of Nutritional Quality (INQ) and the Risk of Obesity in Male Adolescents: a Case-Control Study. 61
32895892 2021
26
Canine and Feline Obesity Management. 61
33653534 2021
27
Danthron ameliorates obesity and MAFLD through activating the interplay between PPARα/RXRα heterodimer and adiponectin receptor 2. 61
33581653 2021
28
Dysfunction of perivascular adipose tissue in mesenteric artery is restored by aerobic exercise in high-fat diet induced obesity. 61
32893373 2021
29
Obesity and incident gastrointestinal cancers: overall body size or central obesity measures, which factor matters? 61
33783379 2021
30
Sex differences in markers of metabolic syndrome and adipose tissue inflammation in obesity-prone, Osborne-Mendel and obesity-resistant, S5B/Pl rats. 61
33662430 2021
31
A haplotype of the ANGPTL3 gene is associated with CVD risk, diabetes mellitus, hypertension, obesity, metabolic syndrome, and dyslipidemia. 61
33636293 2021
32
Potential Ameliorative Effects of Chromium Supplementation on Glucose Metabolism, Obesity, and Genomic Stability in Prediabetic Rat Model. 61
32710349 2021
33
Adults' attitudes toward children, adolescents, and adults who are obese and tax-funded programs to combat obesity. 61
33198607 2021
34
Polysaccharide fraction from greens of Raphanus sativus alleviates high fat diet-induced obesity. 61
33268179 2021
35
A systematic review of neural correlates of dysregulated eating associated with obesity risk in youth. 61
33587960 2021
36
Obesity aggravates COVID-19: An updated systematic review and meta-analysis. 61
33200825 2021
37
Association of infant diet with subsequent obesity at 2-5 years among children exposed to gestational diabetes: the SWIFT study. 61
33495846 2021
38
SLC6A14 deficiency is linked to obesity, fatty liver, and metabolic syndrome but only under conditions of a high-fat diet. 61
33513428 2021
39
Metabolism of testosterone during weight loss in men with obesity. 61
33610798 2021
40
Effects of obesity and diabesity on heart rhythm in the Zucker rat. 61
33609055 2021
41
Genetic ablation of C-reactive protein gene confers resistance to obesity and insulin resistance in rats. 61
33544171 2021
42
Heterogeneity in insulin-stimulated glucose uptake among different muscle groups in healthy lean people and people with obesity. 61
33511440 2021
43
Low cardiorespiratory fitness and obesity for ADHD in childhood and adolescence: A 6-year cohort study. 61
33341993 2021
44
Obesity and ADHD: Exploring the role of body composition, BMI polygenic risk score, and reward system genes. 61
33127071 2021
45
Changes in metabolic and physiological biomarkers in Mangalarga Marchador horses with induced obesity. 61
33641803 2021
46
Thermal Ablation of Renal Cell Carcinoma in Patients With Morbid Obesity: Assessment of Technique, Safety, and Oncologic Outcomes. 61
32755206 2021
47
Editorial Comment on "Thermal Ablation of Renal Cell Carcinoma in Patients With Morbid Obesity: Assessment of Technique, Safety, and Oncologic Outcomes". 61
32812802 2021
48
Circulating adipokine concentrations and risk of five obesity-related cancers: A Mendelian randomization study. 61
33038280 2021
49
Overlapping obesity-related glomerulopathy and immunoglobulin A nephropathy: clinical and pathologic characteristics and prognosis. 61
33811270 2021
50
The influence of obesity on hydroxychloroquine blood levels in lupus nephritis patients. 61
33402039 2021

Variations for Body Mass Index Quantitative Trait Locus 7

Expression for Body Mass Index Quantitative Trait Locus 7

Search GEO for disease gene expression data for Body Mass Index Quantitative Trait Locus 7.

Pathways for Body Mass Index Quantitative Trait Locus 7

GO Terms for Body Mass Index Quantitative Trait Locus 7

Sources for Body Mass Index Quantitative Trait Locus 7

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....